We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ultrasound-guided Radiofrequency Ablation for Early Hepatocellular Carcinoma.
- Authors
Cheng, A. K. C.; Cheung, M.; Chu, E. Y. L.
- Abstract
Objectives: To review the outcome and procedure-related complications of patients who underwent ultrasound-guided percutaneous radiofrequency ablation (RFA) for early hepatocellular carcinoma (HCC). Methods: Medical records of patients who underwent RFA for stage I or IIa solitary HCC between January 2008 and July 2012 were reviewed. Results: 17 men and 5 women aged 50 to 95 (mean, 66.3) years were included. The mean time from diagnosis to RFA was 1.8 months. At a mean follow-up of 1.7 months, 20 of 22 patients had complete ablation and no scar recurrence. At a mean follow-up of >8 months, 16 of 22 patients had no scar recurrence. At a mean follow-up of 36 months, 14 of 22 patients had recurrence, six had no recurrence, and two had died. The mean overall survival was 33.0 months. The overall survival at years 1, 2, and 3 were 100%, 86.4%, and 81.8%, respectively. The mean disease-free survival was 19.0 months. The disease-free survival at years 1, 2, and 3 were 54.5%, 44.4%, and 33.3%, respectively. The mean disease-free survival was longer in patients with a smaller tumour (≤1.8 cm) than those with a larger tumour (>1.8 cm) [27.1 vs. 10.9 months, p = 0.01]. None had procedure-related mortality or major complications. Conclusion: Ultrasound-guided percutaneous RFA is a safe and effective primary treatment for early solitary HCC. Larger tumour is associated with a shorter disease-free survival; frequent follow-up is important.
- Subjects
CATHETER ablation; HEPATOCELLULAR carcinoma; MEDICAL records; METASTASIS; SURVIVAL; ULTRASONIC imaging; PROGNOSIS
- Publication
Hong Kong Journal of Radiology, 2017, Vol 20, Issue 3, p220
- ISSN
2223-6619
- Publication type
Article
- DOI
10.12809/hkjr1715377